Lopez LR, Ahn J-H, Alves T, Arthur JC. Microenvironmental factors that shape bacterial metabolites in inflammatory bowel disease. Front Cell Infect Microbiol. 2022 Jul 15;12:934619. doi: 10.3389/fcimb.2022.934619
Wronski SL, Mordin M, Kelley K, Anguiano RH, Classi P, Shen E, Manaker S. The role of noninvasive endpoints in predicting long-term outcomes in pulmonary arterial hypertension. Lung. 2020 Feb;198(1):65-86. doi: 10.1007/s00408-019-00289-2
Ensor CR, Iasella CJ, Harrigan (Zhang) KM, Morrell MR, Moore CA, Shigemura N, Zeevi A, McDyer JF, Venkataramanan R. Increasing tacrolimus time-in-therapeutic range is associated with superior one-year outcomes in lung transplant recipients. Am J Transplant. 2018 Jun;18(6):1527-33. doi: 10.1111/ajt.14723
Montserrat-Capdevila J, Godoy P, Marsal JR, Barbe F, Pifarre J, Alseda M, Ortega M. Overview of the impact of depression and anxiety in chronic obstructive pulmonary disease. Lung. 2017 Feb;195(1):77-85. doi: 10.1007/s00408-016-9966-0
Lash TL, Johansen MB, Christensen S, Baron JA, Rothman KJ, Hansen JG, Sorensen HT. Hospitalization rates and survival associated with COPD: a nationwide Danish cohort study. Lung. 2011 Feb 1;189(1):27-35.
Rivero E, Varas-Lorenzo C, Maguire AR, Eisen HJ, Pedersen TR, Nashan B, Elkammas E. 10-Year predicted probability of coronary heart disease in renal transplant recipients treated with everolimus or mmf. Poster presented at the American Transplant Congress; April 2002. Washington, DC. [abstract] Am J Transplant. 2002; 2(Suppl 3):418.